Synact Pharma: Funding secured

Research Note

2019-10-21

12:23

This morning Synact announced a capital raise of roughly 30 SEKm through a directed share issue (~13 SEKm) and rights issue (~17.3 SEKm). The capital will primarily be used to finance the full Phase II trial with AP1189 in RA and a Phase II trial in nephrotic syndrome. Overall, we are encouraged by the financing structure and the low discount. Considering the dilution (25%) of the capitalization, we lower our base case to SEK 10 (13).

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.